The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Clinical utility of natural killer cells in cancer therapy and transplantation
Open accessAbstract
Natural killer (NK) cells recognize deranged cells that display stress receptors or loss of major histocompatibility complex (MHC) class I. During development, NK cells become “licensed” only after they encounter cognate human leucocyte antigen (HLA) class I, leading to the acquisition of effector function. NK cells can be exploited for cancer therapy in several ways. These include targeting within monoclonal antibodies alone or combined with ex vivo and in vivo NK cell activation to facilitate adoptive immunotherapy using donor-derived NK cell products to induce graft-vs-tumor effects. In the adoptive transfer setting, persistence and in vivo expansion requires lymphodepleting chemotherapy to prevent rejection and provide homeostatic cytokines (such as IL-15) that activate NK cells. IL-15 has the advantage of avoiding regulatory T-cell expansion. Clinical applications are currently being tested. To enhance in vivo expansion, IL-2 has been used at low doses. However, low dose administration also leads to the stimulation of regulatory T cells. Monoclonal antibodies and bispecific killer engagers (BiKEs) may enhance specificity by targeting CD16 on NK cells to tumor antigens. Inhibition of CD16 shedding may also promote enhanced cytotoxicity. Future strategies include exploiting favorable donor immunogenetics or ex vivo expansion of NK cells from blood, progenitors, or pluripotent cells. Comparative clinical trials are needed to test these approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
Lopez-Vergès, S., Milush, J. M., Schwartz, B. S., Pando, M. J., Jarjoura, J., York, V. A., Houchins, J. P., Miller, S., Kang, S.-M., Norris, P. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110900108 · Cited by 822
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592
IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0993 · Cited by 376
Zhang, Y., Wallace, D. L., De Lara, C. M., Ghattas, H., Asquith, B., Worth, A., Griffin, G. E., Taylor, G. P., Tough, D. F., Beverley, P. C. L., et al. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02573.x · Cited by 376
Cited by
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
The Broad Spectrum of Human Natural Killer Cell Diversity
Freud, A. G., Mundy-Bosse, B. L., Yu, J., & Caligiuri, M. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.008 · Cited by 695
CIS is a potent checkpoint in NK cell–mediated tumor immunity
Delconte, R. B., Kolesnik, T. B., Dagley, L. F., Rautela, J., Shi, W., Putz, E. M., Stannard, K., Zhang, J.-G., Teh, C., Firth, M., et al. (2016) · Nature Immunology · doi:10.1038/ni.3470 · Cited by 384
Activation-Specific Metabolic Requirements for NK Cell IFN-γ Production
Keppel, M. P., Saucier, N., Mah, A. Y., Vogel, T. P., & Cooper, M. A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402099 · Cited by 313
Metadata
- Authors
- Knorr, D. A., Bachanova, V., Verneris, M. R., & Miller, J. S.
- Venue
- Seminars in Immunology
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 26
- Issue
- 2
- Pages
- 161-172
- ISSN
- 1044-5323 (ISSN-L)
- OpenAlex
- W2094668841
- Cited by
- 170
- References
- 8
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical utility of natural killer cells in cancer therapy and transplantation. https://app.cochat.ai/papers/10.1016/j.smim.2014.02.002
- The paper
- Knorr, D. A., Bachanova, V., Verneris, M. R., & Miller, J. S. (2014). Clinical utility of natural killer cells in cancer therapy and transplantation. Seminars in Immunology. https://doi.org/10.1016/j.smim.2014.02.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.